Monday, October 29, 2012

Bank of America/Merrill Lynch- The fight against obesity will be a major investment trend

(Source: Reuters) - The fight against Obesity will be a major investment trend for the next 20-25 years, a report by Bank of America/Merrill Lynch
"Obesity may be the most pressing health challenge facing the world today and efforts to tackle it will shape thinking by policymakers and in boardrooms around the world," said Sarbjit Nahal, equity strategist at BofA Merrill Lynch Global Research. "Global obesity is a mega-investment theme for the next 25 years and beyond."

Source: http://in.reuters.com/article/2012/07/16/us-obesity-report-merrilllynch-idINBRE86F1CT20120716


 

 

ONCIOMED, Inc. Awarded New Patent for a Novel Treatment of Obesity and Diabetes.


Oct 29, 2012

Onciomed, Inc. (Irvine, California), a developer of minimally invasive technologies for the treatment of obesity and diabetes reported that the U.S. Patent and Trademark Office has awarded an additional key patent covering the design and implantation method for its novel device to treat obesity and diabetes. Several additional patents are also currently in review at the patent office which will significantly add to Onciomed’s portfolio.

“The challenge of current treatments is that most of them offer a single mode of action and thus the durability of weight loss is often a problem as the stomach expands over time”, said Dr. Raj Nihalani, president/CEO of Onciomed, Inc. “Our novel VEST technology system was designed to be an alternative to traditional, highly invasive, irreversible bariatric surgery.” It is performed through a single incision laparoscopic procedure, and once in place, the device is intended to be a permanent solution.  The VEST acts as a true restrictive technology to provide feelings of early fullness and satiety along with a faster gastric emptying time leading to a reduced absorption of fat and glucose. Patients can then modify their diet, thereby returning to a healthier lifestyle, and, in turn, reduce their dependence on diabetes medications.

 “These patents further demonstrate the uniqueness of our VEST technology system, using a minimally invasive and reversible approach for obesity treatment and diabetes,” said Dr. Nihalani, president/CEO of Onciomed, Inc. “We are pleased with the claims allowed and believe these patents provide a great foundation for Onciomed to build on as we continually expand our intellectual property position. These patents, along with a high-powered team and a demonstrated animal study and human feasibility, all provide significant confidence to make the Onciomed technology the future standard of care for the minimally invasive leading treatment of obesity and diabetes.”

Onciomed also announced that it will be raising $5M in Series A funding to start enrollment of a clinical trial patients outside the U.S.
Dr Nihalani added, “We have run the company very leanly to date, and have reached milestones that most of the medical device companies accomplish at the Series B round of their financing.”
For additional information contact: Glenn Morimoto at: glennmorimoto@hotmail.com
Ph:415-450-0473 and Santhosh. V at: santhosh.vadivelu@gmail.com ; ph: 650 278-6683

No comments:

Post a Comment